Daniel J. Lippis
At a glance: Daniel J. Lippis is Cvp, Tavr at Edwards Lifesciences (EW). Their latest SEC Form 4, filed Nov 10, 2026, reported a sale of $65K. On file: 0 purchase lines ($0) and 15 sale lines ($989K).
Disclosed holdings: about $4.2M of EW stock: 40,034 shares reported on their latest Form 4 (filed Nov 10, 2026), valued at the Nov 19, 2026 close of $103.72. This counts only EW shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Cvp, Japac at Edwards Lifesciences Corp (EW); Cvp, Tavr at Edwards Lifesciences Corp (EW)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Daniel J. Lippis's InsiderPrint
15 trades from SEC Form 4 filings, 2025 to 2026, drawn as one fingerprint.
Reading this print: Almost only sells, trading about 15 times a year, typically $65K a trade; most sales are on a pre-planned 10b5-1 schedule.
- Bump outward: a purchase (0)
- Dent inward: a sale (15)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Lisa BodensteinerSee Remarks · SYNA · 100% match
- Khurram JamilChief Medical Officer · GALT · 100% match
- Marie MendozaGeneral Counsel · KTOS · 100% match
- Jason AdairChief Business Officer · LQDA · 100% match
- Chad M. SmithCOO · BETR · 100% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Nov 10SEC | EWEdwards Lifesciences Corp | Sell Plan | 61940,034 held (−2%) | $104.25 | $65K | -0.5% |
| Oct 8SEC | EWEdwards Lifesciences Corp | Sell Plan | 61940,034 held (−2%) | $85.65 | $53K | +21.1% |
| Sep 11SEC | EWEdwards Lifesciences Corp | Sell Plan | 61940,034 held (−2%) | $87.51 | $54K | +18.5% |
| Aug 11SEC | EWEdwards Lifesciences Corp | Sell Plan | 61940,034 held (−2%) | $92.03 | $57K | +12.7% |
| Jul 10SEC | EWEdwards Lifesciences Corp | Sell Plan | 61940,034 held (−2%) | $91.70 | $57K | +13.1% |
| Jun 30SEC | EWEdwards Lifesciences Corp | Sell Plan | 61940,411 held (−2%) | $91.40 | $57K | +13.5% |
| May 18SEC | EWEdwards Lifesciences Corp | Sell Plan | 62040,411 held (−2%) | $81.14 | $50K | +27.8% |
| May 4SEC | EWEdwards Lifesciences Corp | Sell Plan | 1934,934 held (−0%) | $83.99 | $2K | +23.5% |
| May 4SEC | EWEdwards Lifesciences Corp | Sell Plan | 1,00033,934 held (−3%) | $82.99 | $83K | +25.0% |
| May 4SEC | EWEdwards Lifesciences Corp | Sell Plan | 1,01933,682 held (−3%) | $83.98 | $86K | +23.5% |
| Apr 6SEC | EWEdwards Lifesciences Corp | Sell Plan | 1,01933,934 held (−3%) | $80.98 | $83K | +28.1% |
| Mar 11SEC | EWEdwards Lifesciences Corp | Sell Plan | 1,01933,934 held (−3%) | $85.38 | $87K | +21.5% |
| Jan 9SEC | EWEdwards Lifesciences Corp | Sell Plan | 1,01922,002 held (−4%) | $85.70 | $87K | +21.0% |
| Dec 12SEC | EWEdwards Lifesciences Corp | Sell Plan | 1,01922,002 held (−4%) | $84.03 | $86K | +23.4% |
| Nov 10SEC | EWEdwards Lifesciences Corp | Sell Plan | 1,02022,002 held (−4%) | $82.55 | $84K | +25.7% |
- Sell
Cvp, Tavr Daniel J. Lippis sold $65K of EW at $104.25 — pre-scheduled 10b5-1 plan sale.
- Sell
Cvp, Tavr Daniel J. Lippis sold $53K of EW at $85.65 — pre-scheduled 10b5-1 plan sale.
- Sell
Cvp, Tavr Daniel J. Lippis sold $54K of EW at $87.51 — pre-scheduled 10b5-1 plan sale.
- Sell
Cvp, Tavr Daniel J. Lippis sold $57K of EW at $92.03 — pre-scheduled 10b5-1 plan sale.
- Sell
Cvp, Tavr Daniel J. Lippis sold $57K of EW at $91.70 — pre-scheduled 10b5-1 plan sale.
- Sell
Cvp, Tavr Daniel J. Lippis sold $57K of EW at $91.40 — pre-scheduled 10b5-1 plan sale.
Follow Daniel J. Lippis
Get one email when Daniel J. Lippis files a new purchase or sale. Free.
At most one email a day about Daniel J. Lippis, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.